Single-agent thalidomide for treatment of first relapse following high-dose chemotherapy in patients with multiple myeloma

Leukemia. 2005 Jan;19(1):156-9. doi: 10.1038/sj.leu.2403564.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / administration & dosage*
  • Dose-Response Relationship, Drug
  • Humans
  • Multiple Myeloma / drug therapy*
  • Recurrence
  • Thalidomide / therapeutic use*
  • Treatment Outcome

Substances

  • Antineoplastic Agents
  • Thalidomide